A Phase 2 interventional study of NAL ER and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Trevi Therapeutics. Completed at 11 sites in United Kingdom. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-29.
Sponsored by Trevi Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom — 14 open to participants now, 22 under way, 4 of them phase 3. Idiopathic Pulmonary Fibrosis · United Kingdom.
Among the 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom, this one is the 57th largest by enrollment of the 83 interventional ones that give a count, is one of 5 that started in 2019, is one of 43 in phase 2, and was the 53rd registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →14 of the 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom are open now. Recruiting first, the newest first:
Chiesi Farmaceutici S.p.A. · Sites in United Kingdom, United States, North Macedonia and 1 more country
Ages 40+
AstraZeneca · Sites in United Kingdom, United States, Argentina and 20 more countries
Ages 40+
Avalyn Pharma Inc. · Sites in United Kingdom, Australia, Canada and 4 more countries
Ages 40+
University Hospital Southampton NHS Foundation Trust · Sites in United Kingdom
Ages 18–85 · Healthy volunteers
Rein Therapeutics · Sites in United Kingdom, United States, Australia and 4 more countries
Ages 40+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 46 · Phase 3 15 · Phase 4 3
First in 2000; this study’s year is marked. 5 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 109 across the 83 interventional studies, 132 across the 20 observational. Of the 73 that completed or were terminated, 39 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
72 of 103 have an industry lead sponsor. The 10 most frequent:
Trevi Therapeutics is the lead sponsor of 17 studies on the registry; 3 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Trevi Therapeutics has 5 studies filed under Idiopathic Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06238622Phase 3Boehringer IngelheimA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | 2027-04-28 |
| NCT06736990Calluna Pharma ASA Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis | 2026-11 |
| NCT07194382Avalyn Pharma Inc.AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF | 2026-12 |
| NCT06588686Vicore Pharma ABA Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. | 2027-05 |
| NCT06488638University Hospital Southampton NHS Foundation TrustPilot Study of Nitrate-rich Beetroot Juice Supplementation in Patients With Idiopathic Pulmonary Fibrosis (IPF) | 2027-06-03 |
Add all 7 to your calendar (.ics) → With an account.
Among the 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and tolerability of nalbuphine ER tablets in the study population and to evaluate the effect of NAL ER tablets on the mean daytime cough frequency (coughs per hour) at Day 22 (dose 162 mg BID) as compared to placebo tablets.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The following conditions are excluded:
Interstitial lung disease (ILD) known to be caused by drug related toxicity.
Participants received NAL ER in treatment period 1 at dose 27 mg once daily (QD) to 54 mg twice daily (BID) over a 5-day period and then maintained at 54 mg BID for 4 days. Dose was increased to 108 mg BID for 1 week then to 162 mg BID for 6 days, followed by placebo matching NAL ER for 3 weeks in treatment period 2. Both the treatment periods were separated by 2 weeks of washout period.
Drug: NAL ER · Drug: Placebo
Participants received placebo matching NAL ER for 3 weeks in treatment period 1 followed by NAL ER in treatment period 2 at dose 27 mg QD to 54 mg BID over a 5-day period and then maintained at 54 mg BID for 4 days. Dose was increased to 108 mg BID for 1 week then to 162 mg BID for 6 days. Both the treatment periods were separated by 2 weeks of washout period.
Drug: NAL ER · Drug: Placebo
Participants received NAL ER 27 mg QD, 27 mg BID, 54 mg BID, 108 mg BID, 162 mg BID.
Also known as: Nalbuphine
Participants received Placebo tablet (matching NAL ER ).
Also known as: Placebo matched to NAL ER
Number of Participants Who Experienced at Least One Treatment Emergent Adverse Events (TEAEs)
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A TEAE was defined as any AE that occurs after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.
Time frame: Up to Day 72
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters
The clinical laboratory parameters included the urinalysis, hematology, serum chemistry, coagulation and liver function parameters. Clinical significance was determined by the investigator.
Time frame: Up to Day 72
Number of Participants With Clinically Significant Changes in Vital Sign Parameters
Vital signs measurements included blood pressure, heart rate, and respiration rate, body temperature, pulse oximetry, and weight. Clinical significance was determined by the investigator.
Time frame: Up to Day 72
Number of Participants With Clinically Significant Changes in Physical Examination Parameters
Physical examination included examination of the following body systems: general appearance, eyes, ears, nose, throat, head and neck, chest and lungs, cardiovascular, abdomen, musculoskeletal, lymphatic, dermatological, neurological, and extremities. Clinical significance was determined by the investigator.
Time frame: Up to Day 72
Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG)
Changes in ECG data such as heart rate, rhythm, and other clinically significant abnormalities (left ventricular hypertrophy, pathological Q-waves) were measured. Clinical significance was determined by the investigator.
Time frame: Up to Day 72
Change From Baseline in Forced Vital Capacity (FVC) at Day 21
Spirometry was used to assess FVC. It was used to assess pulmonary breathing mechanics.
Time frame: Baseline, Day 21
Subjective Opiate Withdrawal (SOWS) Total Raw Score
The SOWS is a self-administered scale for grading opioid withdrawal symptoms and was collected via the study issued e-diary. It consisted of 16 symptoms related to how the participant felt. Each symptom was scored between 0 to 4. The total score ranges between 0 to 64, higher score indicates more severe symptoms.
Time frame: Up to Day 72
Daytime Cough Frequency at Baseline
Daytime cough was defined as cough that occurs between the time that the participant is a wake in the 24 hours after the digital cough monitor was applied for use. Assessment was done using objective digital cough monitoring. Baseline was defined as the last available assessment prior to the first Treatment Period 1 IP intake.
Time frame: At Baseline
Percent Change From Baseline in Daytime Cough Frequency at Day 22
Daytime cough was defined as cough that occurs between the time that the participant is a wake in the 24 hours after the digital cough monitor was applied for use. Assessment was done using objective digital cough monitoring. Percent change in daytime cough frequency (coughs per hour) from baseline was assessed. Baseline was defined as the last available assessment prior to the first Treatment Period 1 IP intake.
Time frame: Baseline, Day 22
Change From Baseline in Daytime Cough Frequency at Day 22
Daytime cough was defined as cough that occurs between the time that the participant wakes up and the time that the participant goes to bed. Assessment was done using objective digital cough monitoring. The change in daytime cough frequency (coughs per hour) from baseline was assessed. Baseline was defined as the last available assessment prior to the first Treatment Period 1 IP intake.
Time frame: Baseline, Day 22
Percent Change From Baseline in 24-Hour Cough Frequency at Day 22
Percent change in 24-hour (combined daytime and nighttime) cough frequency (coughs per hour) from baseline was assessed. Assessment was done using objective digital cough monitoring. Baseline was defined as the last available assessment prior to the first Treatment Period 1 IP intake.
Time frame: Baseline, Day 22
Percent Change From Baseline in Nighttime Cough Frequency at Day 22
Nighttime cough frequency was intended as the average coughs per hour while the participant was flagged as being asleep. Assessment was done using objective digital cough monitoring. Percent change in cough frequency (coughs per hour) from baseline was assessed. Baseline was defined as the last available assessment prior to the first Treatment Period 1 IP intake.
Time frame: Baseline, Day 22
Mean Change From Baseline in the Evaluating Respiratory Symptoms (E-RS) Diary Cough Subscale at Days 9, 16, and 22
E-RS daily diary instrument has four separate respiratory symptom domain scales which is a valid, reliable and sensitive measure of four distinct respiratory symptoms. The four domain scales that included cough \[E-RS item 2- How often did you cough today?;score range 0 (not at all)-4 (almost constantly)\], and other items such as breathlessness \[score 0(not at all)-23(severe symptoms)\], sputum \[0(not at all)-8(severe symptoms)\], and chest symptoms \[0(not at all)-12(severe symptoms)\]. The raw totals for the E-RS score and for each of the subscales were converted to a scale range of 0 to 100 (least symptomatic to most symptomatic). A higher score on the scale indicates a more severe grade to the symptom. Negative score indicates improvement in the symptom. The mean change from baseline in the E-RS diary cough scores was assessed. Baseline was defined as the last available assessment prior to the first Treatment Period 1 IP intake.
Time frame: Baseline, Days 9, 16, and 22
Mean Change From Baseline in E-RS Breathlessness Score at Days 9, 16, and 22
E-RS daily diary instrument has four separate respiratory symptom domain scales which is a valid, reliable and sensitive measure of four distinct respiratory symptoms. The four domain scales included breathlessness \[E-RS items 7 (were you breathless today), 8 (how breathless were you today), 9 (breathlessness doing personal care activities),10 (breathlessness doing indoor activities) \& 11 (breathlessness doing outdoor activities); score =0: not at all) - 23: almost constantly\]. Other items were cough (0: not at all-4: severe), sputum (0: not at all-8: severe), and chest symptoms (0: not at all)-12: severe symptoms). The raw totals for the E-RS score and for subscales were converted to a scale of 0 to 100 (least to most symptoms). Higher score=more severe grade to the symptom. Negative score=improvement in symptom. The mean change from baseline was assessed. Baseline was defined as the last available assessment prior to the first Treatment Period 1 IP intake.
Time frame: Baseline, Days 9, 16, and 22
Mean Change From Baseline in the Cough Severity Numerical Rating Scale (NRS) at Days 8, 15, and 21
The Cough Severity NRS instrument is a single-dimension 11-point Likert scale ranging from 0 (no cough) to 10 (worst possible cough). Negative score indicates improvement in the symptoms. Participants completed the cough numerical severity rating via the study specific e-diary. The mean change from baseline in the Cough Severity Numerical Rating Scale was assessed. Baseline was defined as the last available assessment prior to the first Treatment Period 1 IP intake.
Time frame: Baseline, Days 8, 15, and 21
Mean Change From Baseline in the 14-item EXAcerbation of Chronic Pulmonary Disease Tool (EXACT) v1.1 e-Diary Tool Total Score at Days 9, 16, and 22
The EXACT tool is a 14-item Daily Diary Tool Patient-reported outcome (PRO) instrument that was developed to quantify and measure exacerbations of chronic obstructive pulmonary disease (COPD). It provides a total score and subscale scores for breathlessness, cough and sputum, and chest symptoms. The 14 items have interval-level scale ranging between 0 to 100. The total score of each domain of breathlessness, cough and sputum, and chest symptoms ranges from 0 to 100. A higher score indicates a more severe condition. Negative score indicated improvement in the symptoms. Baseline was defined as the last available assessment prior to the first Treatment Period 1 IP intake.
Time frame: Baseline, Days 9, 16, and 22
Mean Change From Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) Item Bank v1.0 Fatigue Short Form 7a Scale Total Score at Day 21
The PROMIS Fatigue Short Form 7a is a self-administered Likert-type rating 5-point scale of 7 questions that assess tiredness, exhaustion, energy, fatigue limit, tiredness to think, tiredness impact on hygiene and impact on ability to exercise strenuously over the past 7 days. It consisted of 7 items with each item was scored between 1 to 5. The total score could range between 1 to 35, higher score indicates more severe symptoms. Baseline was defined as the last available assessment prior to the first Treatment Period 1 IP intake.
Time frame: Baseline, Day 21
Clinical Global Impression of Change (CGI-C) Over Time Measured at Day 21
The CGI-C is a one-item measure evaluating change from the initiation of treatment on a 7-point scale. It provides an overall clinician-determined summary measure that takes into account all available information, including knowledge of the patient's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the patient's ability to function. The total score ranges between 0 (very much improved) to 7 (very much worse). The lower scores indicate an improvement in respiratory symptoms.
Time frame: At Day 21
Participants were enrolled at 11 sites in the United Kingdom from 29 October 2019 to 27 May 2022.
| Milestone | First NAL ER Then Placebo | First Placebo Then NAL ER |
|---|---|---|
| Started | 21 | 21 |
| Safety analysis set | 20 | 21 |
| Completed | 19 | 19 |
| Not completed | 2 | 2 |
| Withdrew: Covid-19 pandemic restrictions | 0 | 1 |
| Withdrew: Withdrawal by participant | 1 | 0 |
| Withdrew: Protocol deviation | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Milestone | First NAL ER Then Placebo | First Placebo Then NAL ER |
|---|---|---|
| Started | 19 | 19 |
| Completed | 18 | 10 |
| Not completed | 1 | 9 |
| Withdrew: Adverse event | 0 | 6 |
| Withdrew: Covid-19 pandemic restrictions | 1 | 1 |
| Withdrew: Withdrawal by participant | 0 | 2 |
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A TEAE was defined as any AE that occurs after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.
| Participants | NAL ER | Placebo |
|---|---|---|
| Number of Participants Who Experienced at Least One Treatment Emergent Adverse Events (TEAEs) | 35 | 26 |
The clinical laboratory parameters included the urinalysis, hematology, serum chemistry, coagulation and liver function parameters. Clinical significance was determined by the investigator.
| Participants | NAL ER | Placebo |
|---|---|---|
| Urinalysis | 0 | 0 |
| Hematology | 1 | 0 |
| Serum Chemistry | 1 | 1 |
| Coagulation | 0 | 1 |
| Liver Function Parameters | 0 | 0 |
Vital signs measurements included blood pressure, heart rate, and respiration rate, body temperature, pulse oximetry, and weight. Clinical significance was determined by the investigator.
| Participants | NAL ER | Placebo |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Vital Sign Parameters | 0 | 0 |
Physical examination included examination of the following body systems: general appearance, eyes, ears, nose, throat, head and neck, chest and lungs, cardiovascular, abdomen, musculoskeletal, lymphatic, dermatological, neurological, and extremities. Clinical significance was determined by the investigator.
| Participants | NAL ER | Placebo |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Physical Examination Parameters | 0 | 0 |
Changes in ECG data such as heart rate, rhythm, and other clinically significant abnormalities (left ventricular hypertrophy, pathological Q-waves) were measured. Clinical significance was determined by the investigator.
| Participants | NAL ER | Placebo |
|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG) | 1 | 1 |
Spirometry was used to assess FVC. It was used to assess pulmonary breathing mechanics.
| litre(s) | NAL ER | Placebo |
|---|---|---|
| Change From Baseline in Forced Vital Capacity (FVC) at Day 21 | -2.3 ± 5.58 | -1.0 ± 5.56 |
The SOWS is a self-administered scale for grading opioid withdrawal symptoms and was collected via the study issued e-diary. It consisted of 16 symptoms related to how the participant felt. Each symptom was scored between 0 to 4. The total score ranges between 0 to 64, higher score indicates more severe symptoms.
| score on a scale | NAL ER | Placebo |
|---|---|---|
| Subjective Opiate Withdrawal (SOWS) Total Raw Score | 4.7055 ± 5.0019 | 2.4082 ± 3.5561 |
Daytime cough was defined as cough that occurs between the time that the participant is a wake in the 24 hours after the digital cough monitor was applied for use. Assessment was done using objective digital cough monitoring. Baseline was defined as the last available assessment prior to the first Treatment Period 1 IP intake.
| coughs per hour | NAL ER | Placebo |
|---|---|---|
| Daytime Cough Frequency at Baseline | 27.99 ± 23.704 | 27.99 ± 23.704 |
Daytime cough was defined as cough that occurs between the time that the participant is a wake in the 24 hours after the digital cough monitor was applied for use. Assessment was done using objective digital cough monitoring. Percent change in daytime cough frequency (coughs per hour) from baseline was assessed. Baseline was defined as the last available assessment prior to the first Treatment Period 1 IP intake.
| percent change | NAL ER | Placebo |
|---|---|---|
| Percent Change From Baseline in Daytime Cough Frequency at Day 22 | -75.11 (-82.655 to -67.567) | -22.62 (-42.531 to 2.715) |
Daytime cough was defined as cough that occurs between the time that the participant wakes up and the time that the participant goes to bed. Assessment was done using objective digital cough monitoring. The change in daytime cough frequency (coughs per hour) from baseline was assessed. Baseline was defined as the last available assessment prior to the first Treatment Period 1 IP intake.
| coughs per hour | NAL ER | Placebo |
|---|---|---|
| Change From Baseline in Daytime Cough Frequency at Day 22 | -19.386 ± 19.5688 | -6.264 ± 12.4006 |
Percent change in 24-hour (combined daytime and nighttime) cough frequency (coughs per hour) from baseline was assessed. Assessment was done using objective digital cough monitoring. Baseline was defined as the last available assessment prior to the first Treatment Period 1 IP intake.
| percent change | NAL ER | Placebo |
|---|---|---|
| Percent Change From Baseline in 24-Hour Cough Frequency at Day 22 | -76.10 (-83.133 to -69.075) | -25.29 (-43.894 to -6.690) |
Nighttime cough frequency was intended as the average coughs per hour while the participant was flagged as being asleep. Assessment was done using objective digital cough monitoring. Percent change in cough frequency (coughs per hour) from baseline was assessed. Baseline was defined as the last available assessment prior to the first Treatment Period 1 IP intake.
| percent change | NAL ER | Placebo |
|---|---|---|
| Percent Change From Baseline in Nighttime Cough Frequency at Day 22 | -62.27 (-79.588 to -44.957) | -20.30 (-51.391 to 10.783) |
E-RS daily diary instrument has four separate respiratory symptom domain scales which is a valid, reliable and sensitive measure of four distinct respiratory symptoms. The four domain scales that included cough \[E-RS item 2- How often did you cough today?;score range 0 (not at all)-4 (almost constantly)\], and other items such as breathlessness \[score 0(not at all)-23(severe symptoms)\], sputum \[0(not at all)-8(severe symptoms)\], and chest symptoms \[0(not at all)-12(severe symptoms)\]. The raw totals for the E-RS score and for each of the subscales were converted to a scale range of 0 to 100 (least symptomatic to most symptomatic). A higher score on the scale indicates a more severe grade to the symptom. Negative score indicates improvement in the symptom. The mean change from baseline in the E-RS diary cough scores was assessed. Baseline was defined as the last available assessment prior to the first Treatment Period 1 IP intake.
| score on a scale | NAL ER | Placebo |
|---|---|---|
| Change at Day 9 | -0.7 ± 0.77 | -0.1 ± 0.70 |
| Change at Day 16 | -0.9 ± 0.82 | -0.2 ± 0.59 |
| Change at Day 22 | -1.0 ± 0.94 | -0.2 ± 0.85 |
E-RS daily diary instrument has four separate respiratory symptom domain scales which is a valid, reliable and sensitive measure of four distinct respiratory symptoms. The four domain scales included breathlessness \[E-RS items 7 (were you breathless today), 8 (how breathless were you today), 9 (breathlessness doing personal care activities),10 (breathlessness doing indoor activities) \& 11 (breathlessness doing outdoor activities); score =0: not at all) - 23: almost constantly\]. Other items were cough (0: not at all-4: severe), sputum (0: not at all-8: severe), and chest symptoms (0: not at all)-12: severe symptoms). The raw totals for the E-RS score and for subscales were converted to a scale of 0 to 100 (least to most symptoms). Higher score=more severe grade to the symptom. Negative score=improvement in symptom. The mean change from baseline was assessed. Baseline was defined as the last available assessment prior to the first Treatment Period 1 IP intake.
| score on a scale | NAL ER | Placebo |
|---|---|---|
| Change at Day 9 | -0.5 ± 2.68 | 1.1 ± 2.74 |
| Change at Day 16 | 0.0 ± 2.30 | 1.2 ± 2.26 |
| Change at Day 22 | 0.1 ± 2.45 | 0.8 ± 2.43 |
The Cough Severity NRS instrument is a single-dimension 11-point Likert scale ranging from 0 (no cough) to 10 (worst possible cough). Negative score indicates improvement in the symptoms. Participants completed the cough numerical severity rating via the study specific e-diary. The mean change from baseline in the Cough Severity Numerical Rating Scale was assessed. Baseline was defined as the last available assessment prior to the first Treatment Period 1 IP intake.
| score on a scale | NAL ER | Placebo |
|---|---|---|
| Change at Day 8 | -1.7 ± 1.98 | -0.4 ± 1.54 |
| Change at Day 15 | -2.7 ± 1.75 | -0.6 ± 1.74 |
| Change at Day 21 | -2.5 ± 2.19 | -0.3 ± 1.85 |
The EXACT tool is a 14-item Daily Diary Tool Patient-reported outcome (PRO) instrument that was developed to quantify and measure exacerbations of chronic obstructive pulmonary disease (COPD). It provides a total score and subscale scores for breathlessness, cough and sputum, and chest symptoms. The 14 items have interval-level scale ranging between 0 to 100. The total score of each domain of breathlessness, cough and sputum, and chest symptoms ranges from 0 to 100. A higher score indicates a more severe condition. Negative score indicated improvement in the symptoms. Baseline was defined as the last available assessment prior to the first Treatment Period 1 IP intake.
| score on a scale | NAL ER | Placebo |
|---|---|---|
| Change at Day 9 | -2.0 ± 5.63 | 1.6 ± 5.55 |
| Change at Day 16 | -1.8 ± 4.89 | 1.9 ± 5.46 |
| Change at Day 22 | -1.6 ± 5.92 | 0.6 ± 5.76 |
The PROMIS Fatigue Short Form 7a is a self-administered Likert-type rating 5-point scale of 7 questions that assess tiredness, exhaustion, energy, fatigue limit, tiredness to think, tiredness impact on hygiene and impact on ability to exercise strenuously over the past 7 days. It consisted of 7 items with each item was scored between 1 to 5. The total score could range between 1 to 35, higher score indicates more severe symptoms. Baseline was defined as the last available assessment prior to the first Treatment Period 1 IP intake.
| score on a scale | NAL ER | Placebo |
|---|---|---|
| Mean Change From Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) Item Bank v1.0 Fatigue Short Form 7a Scale Total Score at Day 21 | 0.9 ± 3.98 | 0.0 ± 2.98 |
The CGI-C is a one-item measure evaluating change from the initiation of treatment on a 7-point scale. It provides an overall clinician-determined summary measure that takes into account all available information, including knowledge of the patient's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the patient's ability to function. The total score ranges between 0 (very much improved) to 7 (very much worse). The lower scores indicate an improvement in respiratory symptoms.
| score on a scale | NAL ER | Placebo |
|---|---|---|
| Clinical Global Impression of Change (CGI-C) Over Time Measured at Day 21 | 3.0 ± 1.50 | 3.9 ± 0.91 |
Collected over Up to Day 72. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NAL ER | 0/42 (0%) | 1/38 (2.6%) | 35/38 (92.1%) |
| Placebo | 0/42 (0%) | 1/40 (2.5%) | 26/40 (65%) |
| Event | NAL ER | Placebo |
|---|---|---|
| UrosepsisInfections and infestations | 1/38 | 0/40 |
| PneumoniaInfections and infestations | 0/38 | 1/40 |
| Event | NAL ER | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 16/38 | 0/40 |
| FatigueGeneral disorders | 12/38 | 3/40 |
| ConstipationGastrointestinal disorders | 11/38 | 2/40 |
| DizzinessNervous system disorders | 10/38 | 0/40 |
| SomnolenceNervous system disorders | 9/38 | 1/40 |
| VomitingGastrointestinal disorders | 7/38 | 5/40 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 6/38 | 2/40 |
| DiarrhoeaGastrointestinal disorders | 3/38 | 6/40 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/38 | 6/40 |
| HeadacheNervous system disorders | 5/38 | 5/40 |
Randomized analysis set included all participants who were randomized.
| Age, Customized(years) | First NAL ER Then Placebo | First Placebo Then NAL ER | Total |
|---|---|---|---|
| 18-64 years | 3 | 1 | 4 |
| 65-85 years | 18 | 19 | 37 |
| 85 years and above | 0 | 1 | 1 |
| Sex: Female, Male(Participants) | First NAL ER Then Placebo | First Placebo Then NAL ER | Total |
|---|---|---|---|
| Female | 2 | 4 | 6 |
| Male | 19 | 17 | 36 |
| Race/Ethnicity, Customized(Participants) | First NAL ER Then Placebo | First Placebo Then NAL ER | Total |
|---|---|---|---|
| Asian | 1 | 3 | 4 |
| White | 20 | 18 | 38 |
| Race/Ethnicity, Customized(Participants) | First NAL ER Then Placebo | First Placebo Then NAL ER | Total |
|---|---|---|---|
| Not Hispanic or Latino | 20 | 20 | 40 |
| Not Reported | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2019 to primary completion in May 2022, 30 months.
Results were first posted in May 2025, 3 years after primary completion. A results delay was requested in May 2023.
Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 48. This study's 30 months is above that.
Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nalbuphine
Idiopathic Pulmonary Fibrosis →